LONDON and WELLINGTON, New Zealand, Nov. 14, 2016 /PRNewswire/ -- Volpara Solutions today announced that volumetric breast density percentages generated by VolparaDensity software have been incorporated into the latest version of the Tyrer-Cuzick Breast Cancer Risk Assessment Tool. Despite being recognized as a major independent risk factor for cancer, breast density has not previously been included into a major breast cancer risk model.
The Tyrer-Cuzick Tool is the first widely recognized risk model that includes family history, genetic factors and breast density. The tool accepts three breast density measurement methods, including VolparaDensity, which provides a woman's volumetric breast density percentage, and two visual assessment techniques. The Tyrer-Cuzick Tool calibrates the risk according to the breast density measurement method used. The Tyrer-Cuzick Risk Assessment Tool informs doctors of a woman's risk of developing breast cancer and helps them make decisions about genetic testing and supplemental breast cancer screening. The Tyrer-Cuzick model incorporates family history, endogenous hormonal factors, benign disease, risk factors such as age and body mass index, as well as genetic factors (including BRCA) into a single statistical model. It estimates the likelihood of a woman developing breast cancer within 10 years of her current age and over the course of her lifetime. Independent clinical studies have shown the Tyrer-Cuzick model to be the most consistently accurate when compared with other available risk assessment models. "Multiple studies have demonstrated that mammographic density is a strong breast cancer risk factor. After extensive independent testing on multiple data sets, we are pleased to now incorporate volumetric breast density percentages from VolparaDensity as one method of adding breast density into our risk assessment tool. VolparaDensity has strong predictive value, which we believe will help identify high-risk women and guide clinical decisions about adjunctive screening options based on their specific risk factors," said Jack Cuzick, PhD, FRS, John Snow Professor of Epidemiology, Director, Wolfson Institute of Preventive Medicine, Queen Mary University of London. Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is in use at sites across the globe helping radiologists assess breast density more objectively and helping them better consider who might benefit from additional screening. Volpara Solutions technologies, including VolparaDensity, are currently in use in 35 countries, and more than 9 million women have had their breast density analyzed using VolparaDensity.